


Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 14 (2004) 3363

Corrigendum

Corrigendum to "Bridged bicyclic vasopressin receptor antagonists with V_2 -selective or dual V_{1a}/V_2 activity"

[Bioorg. Med. Chem. Lett. 12 (2002) 3081]

Alexey B. Dyatkin, a,* William J. Hoekstra, Dennis J. Hlasta, Patricia Andrade-Gordon, Lawrence de Garavilla, Keith T. Demarest, Joseph W. Gunnet, William Hageman, Richard Look and Bruce E. Maryanoff a,*

^aDrug Discovery, Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477-0776, USA ^bDrug Discovery, Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ 08869-0602, USA

The authors regret that compound numbers 4 and 5 were inadvertently interchanged in parts of this paper.

Line 3 of the Abstract should read: '... resulted in potent V₂-selective (e.g., 5) and ...'

Page 3081, column 2, lines 13-15 should read: '... as exemplified by derivative 5 and 10. Compound 5, with the R absolute configuration, shows...'

Page 3082, column 2, line 9–10 should read: 'In contrast, 5 (the R-enantiomer of 4) was V₂-selective'.

Page 3084, column 2, line 2 should read: '... resulted in V₂-selective (e.g., 5) and ...'

^{*} DOI of original article: 10.1016/S0960-894X(02)00649-2

^{*}Corresponding authors. Tel.: +1-215-628-5008 (A.B.D.); tel.: +1-215-628-5530; fax: +1-215-628-4985 (B.E.M.); e-mail addresses: adyatkin@prdus.ini.com; bmaryano@prdus.jnj.com